IP Library › Granted Patent US 6,955,919
Granted Patent B2
US 6,955,919 · App. 10/112,894 · Granted Oct 18, 2005

Lentiviral packaging cells and uses therefor

Assignee: Genetix Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,955,919
App. No.
10/112,894
Granted
Oct 18, 2005
Kind
B2
Abstract

Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.

Claims (14)

1. A retroviral packaging cell line comprising:

a first vector comprising a retroviral gag gene, wherein said gag gene encodes retroviral matrix, capsid and nucleocapsid proteins;

a second vector comprising a portion of a retroviral pol gene, fused to a Vpr or Vpx gene, wherein said portion of said pol gene encodes a retroviral protease;

a third vector comprising the remainder of the retroviral pol gene not contained in said second vector, fused to a Vpr or a Vpx gene, wherein said remainder of said pol gene encodes a retroviral reverse transcriptase and a retroviral integrase; and

a fourth vector comprising a viral env gene.

2. The packaging cell line of claim 1 , wherein the retrovirus is a lentivirus.

3. The packaging cell line of claim 2 , wherein the lentivirus is selecting from the group consisting of HIV-1, HIV-2, SIV, FIV and EIV.

4. The packaging cell line of claim 1 , further comprising retroviral accessory genes.

5. The packaging cell line of claim 1 , wherein said remainder of said retroviral pol gene further comprises a protease cleavage site upstream from said reverse transcriptase and said integrase.

6. The packaging cell line of claim 1 , wherein said third vector further comprises a retroviral Vif gene.

7. The packaging cell line of claim 1 , wherein said viral env gene within said third vector encodes an envelope protein selected from a virus selected from the group consisting of a Type C retrovirus, a lentivirus and Vesicular Stomatitis Virus.

8. The packaging cell line of claim 1 , wherein transcription of any one of said genes within said vectors is driven by an inducible promoter.

9. The packaging cell line of claim 1 , wherein transcription of any one of said genes within said vectors is induced by contact of Cre recombinase with one or more Lox sites contained in said vector.

10. The packaging cell line of claim 1 , further comprising a fifth vector comprising a packaging signal, a viral long terminal repeat (LTR), and a transgene, wherein co-expression of said fourth vector with said first, second, and third vectors, in said packaging cell line, results in the production of a recombinant, helper-free retrovirus containing said transgene.

Continuity (3)
Continuation 0931168400 · May 13, 1999
Provisional Application 6008528300 · May 13, 1998
Related Publication 20020168346A1 · Nov 14, 2002